Organisation in KOLN
EUROPEAN RESEARCH INITIATIVE ON CLL EV
In 0 Bekanntmachungen genannt, seit 1. Januar 2023, aber in keiner als Auftragnehmer eines Zuschlags.
Fördermittel
Kohesio und Finanztransparenzsystem der EU, so gezählt.
4 Förderungen, zusammen 241.440 €.
| Quelle | Balken | Betrag | Förderungen |
|---|---|---|---|
| EU-Haushalt (Finanztransparenzsystem) | 241.440 €4 | 4 |
| Jahr | Programm | Projekt | Betrag und Beleg |
|---|---|---|---|
| 2023 | EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101136502 - RESOLVE - RESIDUAL DISEASE ASSESSMENT IN HEMATOLOGIC MALIGNANCIES TO IMPROVE PATIENT-RELEVANT OUTCOMES ACROSS EUROPE (RESOLVE) | 101136502 - RESOLVE - RESIDUAL DISEASE ASSESSMENT IN HEMATOLOGIC MALIGNANCIES TO IMPROVE PATIENT-RELEVANT OUTCOMES ACROSS EUROPE (RESOLVE) | 160.965 €Beleg: Förderung 2023/JAG.1386981.1, Empfänger 87628Mittelbindung |
| 2023 | EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101136502 - RESOLVE - RESIDUAL DISEASE ASSESSMENT IN HEMATOLOGIC MALIGNANCIES TO IMPROVE PATIENT-RELEVANT OUTCOMES ACROSS EUROPE (RESOLVE) | 101136502 - RESOLVE - RESIDUAL DISEASE ASSESSMENT IN HEMATOLOGIC MALIGNANCIES TO IMPROVE PATIENT-RELEVANT OUTCOMES ACROSS EUROPE (RESOLVE) | 66.285 €Beleg: Förderung 2023/JAG.1386981.2, Empfänger 87647Mittelbindung |
| 2023 | EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101136502 - RESOLVE - RESIDUAL DISEASE ASSESSMENT IN HEMATOLOGIC MALIGNANCIES TO IMPROVE PATIENT-RELEVANT OUTCOMES ACROSS EUROPE (RESOLVE) | 101136502 - RESOLVE - RESIDUAL DISEASE ASSESSMENT IN HEMATOLOGIC MALIGNANCIES TO IMPROVE PATIENT-RELEVANT OUTCOMES ACROSS EUROPE (RESOLVE) | 5.963 €Beleg: Förderung 2023/JAG.1386981.3, Empfänger 87682Mittelbindung |
| 2023 | EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101136502 - RESOLVE - RESIDUAL DISEASE ASSESSMENT IN HEMATOLOGIC MALIGNANCIES TO IMPROVE PATIENT-RELEVANT OUTCOMES ACROSS EUROPE (RESOLVE) | 101136502 - RESOLVE - RESIDUAL DISEASE ASSESSMENT IN HEMATOLOGIC MALIGNANCIES TO IMPROVE PATIENT-RELEVANT OUTCOMES ACROSS EUROPE (RESOLVE) | 8.227 €Beleg: Förderung 2023/JAG.1386981.4, Empfänger 87678Mittelbindung |
Angaben aus den Bekanntmachungen
0 Nennungen seit 1. Januar 2023, zuletzt am 1. Januar 2023, dieser Organisation zugeordnet. Wie wir zuordnen
- Anschrift
- JOSEPH STELZMANN STRASSE 9, 50924 KOLN
- USt-IdNr.
- DE300202219
- Schreibweisen
- EUROPEAN RESEARCH INITIATIVE ON CLL EV